{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:36:44Z","timestamp":1762375004653},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1995,2,1]],"date-time":"1995-02-01T00:00:00Z","timestamp":791596800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1995,2]]},"DOI":"10.1007\/bf02246213","type":"journal-article","created":{"date-parts":[[2005,11,15]],"date-time":"2005-11-15T08:45:15Z","timestamp":1132044315000},"page":"417-423","source":"Crossref","is-referenced-by-count":117,"title":["A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia"],"prefix":"10.1007","volume":"117","author":[{"given":"D. C.","family":"Goff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Sarid-Segal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. K.","family":"Midha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. W.","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02246213_CR1","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1987","unstructured":"American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, Third Edition, Revised, American Psychiatric Press, Washington, DC","edition":"Third Edition"},{"key":"BF02246213_CR2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1476-5381.1990.tb14094.x","volume":"100","author":"LI Backus","year":"1990","unstructured":"Backus LI, Sharp T, Grahame-Smith DG (1990) Behavioral evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors. Br J Pharmacol 100:793\u2013799","journal-title":"Br J Pharmacol"},{"key":"BF02246213_CR3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0006-8993(92)90754-W","volume":"579","author":"RJ Baldessarini","year":"1992","unstructured":"Baldessarini RJ, Marsh ER, Kula NS (1992) Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions. Brain Res 579:152\u2013156","journal-title":"Brain Res"},{"key":"BF02246213_CR4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF00426037","volume":"62","author":"JJ Balsara","year":"1979","unstructured":"Balsara JJ, Jadhav JH, Chandorkar AG (1979) Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology 62:67\u201369","journal-title":"Psychopharmacology"},{"key":"BF02246213_CR5","first-page":"18","volume":"26","author":"CMJ Beasley","year":"1990","unstructured":"Beasley CMJ, Bosomworth JC, Wernicke JF (1990) Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 26:18\u201324","journal-title":"Psychopharmacol Bull"},{"key":"BF02246213_CR6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1176\/ajp.140.12.1650","volume":"140","author":"RE Becker","year":"1983","unstructured":"Becker RE (1983) Implications of the efficacy of thiothixene and a chlorpromazine-imipramine combination for depression in schizophrenia. Am J Psychiatry 140:208\u2013211","journal-title":"Am J Psychiatry"},{"key":"BF02246213_CR7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/schbul\/14.2.297","volume":"14","author":"A Bleich","year":"1988","unstructured":"Bleich A, Brown S-L, Kahn R (1988) The role of serotonin in schizophrenia. Schizophr Bull 14:297\u2013314","journal-title":"Schizophr Bull"},{"key":"BF02246213_CR8","first-page":"1352","volume":"146","author":"RH Bouchard","year":"1989","unstructured":"Bouchard RH, Pourcher E, Vincent P (1989) Fluoxetine and extrapyramidal side effects (letter). Am J Psychiatry 146:1352\u20131353","journal-title":"Am J Psychiatry"},{"key":"BF02246213_CR9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1176\/ajp.146.10.1353","volume":"146","author":"TM Brod","year":"1989","unstructured":"Brod TM (1989) Fluoxetine and extrapyramidal side effects (letter). Am J Psychiatry 146:1353","journal-title":"Am J Psychiatry"},{"key":"BF02246213_CR10","first-page":"1403","volume":"148","author":"C Budman","year":"1991","unstructured":"Budman C, Bruun R (1991) Persistent dyskinesia in patient receiving fluoxetine (letter). Am J Psychiatry 148:1403","journal-title":"Am J Psychiatry"},{"key":"BF02246213_CR11","first-page":"272","volume":"53","author":"JW Cain","year":"1992","unstructured":"Cain JW (1992) Poor response to fluoxetine: Underlying depression, serotonergic overstimulation, or a \u201ctherapeutic window\u201d? J Clin Psychiatry 53:272\u2013277","journal-title":"J Clin Psychiatry"},{"key":"BF02246213_CR12","first-page":"278","volume":"53","author":"CF Caley","year":"1992","unstructured":"Caley CF, Friedman JH (1992) Does fluoxetine exacerbate parkinson's disease? J Clin Psychiatry 53:278\u2013282","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"BF02246213_CR13","first-page":"267p","volume":"60","author":"CJ Carter","year":"1977","unstructured":"Carter CJ, Pycock CJ (1977) Possible importance of 5-hydroxytryptamine in neuroleptic-induced catalepsy in rats. Br J Pharmacol 60(2):267p-268p","journal-title":"Br J Pharmacol"},{"key":"BF02246213_CR14","first-page":"1274","volume":"149","author":"SL Cassady","year":"1992","unstructured":"Cassady SL, Thaker GK (1992) Addition of fluoxetine to clozapine (letter). Am J Psychiatry 149:1274","journal-title":"Am J Psychiatry"},{"key":"BF02246213_CR15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00004714-199002000-00009","volume":"10","author":"DA Ciraulo","year":"1990","unstructured":"Ciraulo DA, Shader RI (1990) Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics. J Clin Psychopharmacol 10:48\u201350","journal-title":"J Clin Psychopharmacol"},{"key":"BF02246213_CR16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00007691-198905000-00022","volume":"11","author":"JK Cooper","year":"1989","unstructured":"Cooper JK, Hawes EM, Hubbard JW, McKay G, Midha KK (1989) An ultrasensitive method for the measurement of fluphenazine in plasma by high performance liquid chromatography with coulometric detection. Ther Drug Monit 11:354\u2013360","journal-title":"Ther Drug Monit"},{"key":"BF02246213_CR17","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0028-3908(75)90114-8","volume":"14","author":"B Costall","year":"1975","unstructured":"Costall B, Fortune DH, Naylor RJ (1975) Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology 14:859\u2013868","journal-title":"Neuropharmacology"},{"key":"BF02246213_CR18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0165-1781(91)90125-9","volume":"36","author":"P Czobor","year":"1990","unstructured":"Czobor P, Bitter I, Volavka J (1990) Relationship between the Brief Psychiatric Rating Scale and the Scale for Assessment of Negative Symptoms: a study of their correlation and redundancy. Psychiatry Res 36:129\u2013139","journal-title":"Psychiatry Res"},{"key":"BF02246213_CR19","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1471-4159.1980.tb07879.x","volume":"35","author":"JS Belleroche De","year":"1980","unstructured":"De Belleroche JS, Bradford HF (1980) Presynaptic control of the synthesis and release of dopamine from striatal synaptosomes: a comparison between the effects of 5-hydroxytryptamine, acetylcholine, and glutamate. J Neurochem 35:1227\u20131234","journal-title":"J Neurochem"},{"key":"BF02246213_CR20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF01276578","volume":"55","author":"JS Belleroche De","year":"1982","unstructured":"De Belleroche JS, Gardiner IM (1982) Contrasting effects of 5-hydroxytryptamine on the release of dopamine and acetyl-choline in the nucleus accumbens of rat. J Neural Transm 55:227\u2013242","journal-title":"J Neural Transm"},{"key":"BF02246213_CR21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0006-8993(87)90683-4","volume":"411","author":"MG Simoni De","year":"1987","unstructured":"De Simoni MG, Dal Toso G, Fodritto F, Sokola A, Algeri S (1987) Modulation of striatal dopamine metabolism by the activity of dorsal raphe serotonergic afferences. Brain Res 411:81\u201388","journal-title":"Brain Res"},{"key":"BF02246213_CR22","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/j.1471-4159.1981.tb00594.x","volume":"36","author":"C Ennis","year":"1981","unstructured":"Ennis C, Kemp J, Cox B (1981) Characterization of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in striatum. J Neurochem 36:1515\u20131520","journal-title":"J Neurochem"},{"key":"BF02246213_CR23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00004714-199104000-00022","volume":"11","author":"B Fallon","year":"1991","unstructured":"Fallon B, Liebowitz M (1991) Fluoxetine and extrapyramidal symptoms in CNS lupus (letter). J Clin Psychopharmocol 11:147\u2013148","journal-title":"J Clin Psychopharmocol"},{"key":"BF02246213_CR24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/med.2610110103","volume":"11","author":"RW Fuller","year":"1991","unstructured":"Fuller RW, Wong DT, Robertson W (1991) Fluoxetine, a selective inhibitor of serotonin uptake. Med Res Rev 11:17\u201334","journal-title":"Med Res Rev"},{"key":"BF02246213_CR25","first-page":"325","volume":"9","author":"Y Gelders","year":"1986","unstructured":"Gelders Y, Van den Bussche G, Reyntjens A (1986) Serotonin S-2 receptor blockers in the treatment of chronic schizophrenia. Clin Neuropharmacol 9:325\u2013327","journal-title":"Clin Neuropharmacol"},{"key":"BF02246213_CR26","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1176\/ajp.147.4.492","volume":"147","author":"D Goff","year":"1990","unstructured":"Goff D, Brotman A, Waites M, McCormick S (1990) Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 147:492\u2013494","journal-title":"Am J Psychiatry"},{"key":"BF02246213_CR27","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1176\/ajp.148.6.790","volume":"148","author":"D Goff","year":"1991","unstructured":"Goff D, Midha K, Brotman A, Waites M, Baldessarini R (1991) Elevation of plasma concentrations of haloperidol after addition of fluoxetine. Am J Psychiatry 148:790\u2013792","journal-title":"Am J Psychiatry"},{"key":"BF02246213_CR28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1176\/jnp.2.4.429","volume":"2","author":"MB Goldman","year":"1990","unstructured":"Goldman MB, Janecek HM (1990) Adjunctive fluoxetine improves global function in chronic schizophrenia. J Neuropsychiatr 2:429\u2013431","journal-title":"J Neuropsychiatr"},{"key":"BF02246213_CR29","first-page":"683","volume":"148","author":"MD Gross","year":"1991","unstructured":"Gross MD (1991) Treatment of pathological jealousy by fluoxetine (letter). Am J Psychiatry 148:683\u2013684","journal-title":"Am J Psychiatry"},{"key":"BF02246213_CR30","volume-title":"ECDEU Assessment manual for psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W (1976). ECDEU Assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Washington, DC"},{"key":"BF02246213_CR31","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/0006-3223(90)90485-K","volume":"28","author":"M Halman","year":"1990","unstructured":"Halman M, Goldbloom DS (1990) Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 28:518\u2013521","journal-title":"Biol Psychiatry"},{"key":"BF02246213_CR32","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/BF02245005","volume":"112","author":"T Hashimoto","year":"1993","unstructured":"Hashimoto T, Kitamura N, Kajimoto Y, Shirai Y, Shirakawa O, Mita T, Nishino N, Tanaka C (1993) Differential changes in serotonin 5HT1A and 5HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology 112:S35-S39","journal-title":"Psychopharmacology"},{"key":"BF02246213_CR33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0006-8993(87)91588-5","volume":"435","author":"D Herve","year":"1987","unstructured":"Herve D, Pickel VM, Joh TH, Beaudet A (1987) Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res 435: 71\u201383","journal-title":"Brain Res"},{"key":"BF02246213_CR34","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00004714-199010000-00007","volume":"10","author":"R Hoehn-Saric","year":"1990","unstructured":"Hoehn-Saric R, Lipsey J, McLeod D (1990) Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol 10: 343\u2013345","journal-title":"J Clin Psychopharmacol"},{"key":"BF02246213_CR35","first-page":"131","volume":"52","author":"R Hoehn-Saric","year":"1991","unstructured":"Hoehn-Saric R, Harris GJ, Pearlson GD, Cox CS, Machlin SR, Camargo EE (1991) A fluoxetine-induced frontal lobe syndrome in an obsessive-compulsive patient. J Clin Psychiatry 52: 131\u2013133","journal-title":"J Clin Psychiatry"},{"key":"BF02246213_CR36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0006-8993(88)90694-4","volume":"457","author":"D Jackson","year":"1988","unstructured":"Jackson D, Stachowiak MK, Bruno JP, Zigmond MJ (1988) Inhibition of striatal acetylcholine release by endogenous serotonin. Brain Res 457: 259\u2013266","journal-title":"Brain Res"},{"key":"BF02246213_CR37","doi-asserted-by":"crossref","first-page":"277S","DOI":"10.1111\/j.1365-2125.1983.tb05876.x","volume":"15","author":"P Jenner","year":"1983","unstructured":"Jenner P, Sheehy M, Marsden CD (1983) Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of parkinson's disease. Br J Clin Pharmacol 15: 277S-289S","journal-title":"Br J Clin Pharmacol"},{"key":"BF02246213_CR38","first-page":"600","volume":"17","author":"G Kennett","year":"1991","unstructured":"Kennett G, Blackburn T (1991) Evidence for modulation of dopamine release by 5HT3 receptors within the nucleus accumbens. Soc Neurosci Abstr 17: 600","journal-title":"Soc Neurosci Abstr"},{"key":"BF02246213_CR39","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/330746a0","volume":"330","author":"G Kilpatrick","year":"1987","unstructured":"Kilpatrick G, Jones B, Tyers M (1987) Identification and distribution of 5HT3 receptors in rat brain using radioligand binding. Nature 330: 746\u2013748","journal-title":"Nature"},{"key":"BF02246213_CR40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0014-2999(85)90135-9","volume":"118","author":"S Korsgaard","year":"1985","unstructured":"Korsgaard S, Gerlach J, Christensson E (1985) Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmacol 118: 245\u2013252","journal-title":"Eur J Pharmacol"},{"key":"BF02246213_CR41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0006-8993(72)90208-9","volume":"48","author":"W Kostowski","year":"1972","unstructured":"Kostowski W, Gumulka W, Czlonkowski A (1972) Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated withp-chlorophenylalanine. Brain Res 48: 443\u2013446","journal-title":"Brain Res"},{"key":"BF02246213_CR42","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/archpsyc.1989.01810100064012","volume":"46","author":"M Kramer","year":"1989","unstructured":"Kramer M, Vogel W, DiJohnson C, Dewey D, Sheves P, Cavicchia S, Litle P, Schmidt R, Kimes I (1989) Antidepressants in \u201cdepressed\u201d schizophrenic inpatients: a controlled trial. Arch Gen Psychiatry 46: 922\u2013928","journal-title":"Arch Gen Psychiatry"},{"key":"BF02246213_CR43","first-page":"345","volume":"51","author":"RD Lane","year":"1990","unstructured":"Lane RD (1990) Successful fluoxetine treatment of pathological jealousy. J Clin Psychopharmacol 51: 345\u2013346","journal-title":"J Clin Psychopharmacol"},{"key":"BF02246213_CR44","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1007\/BF02245006","volume":"112","author":"JE Leysen","year":"1993","unstructured":"Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology 112: S40-S54","journal-title":"Psychopharmacology"},{"key":"BF02246213_CR45","first-page":"339","volume":"50","author":"JF Lipinski","year":"1989","unstructured":"Lipinski JF, Mallya G, Zimmerman P, Pope HG (1989) Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 50: 339\u2013342","journal-title":"J Clin Psychiatry"},{"key":"BF02246213_CR46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00004714-199010000-00031","volume":"10","author":"J Lock","year":"1990","unstructured":"Lock J, Gwirtsman H, Targ E (1990) Possible adverse drug interactions between fluoxetine and other psychotropics (letter). J Clin Psychopharmacol 10: 383\u2013384","journal-title":"J Clin Psychopharmacol"},{"key":"BF02246213_CR47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00005053-199001000-00011","volume":"178","author":"GE Mandalos","year":"1990","unstructured":"Mandalos GE, Szarek BL (1990) Dose-related paranoid reaction associated with fluoxetine. J Nerv Ment Dis 178: 57\u201358","journal-title":"J Nerv Ment Dis"},{"key":"BF02246213_CR48","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1176\/ajp.148.8.1064","volume":"148","author":"PJ Markovitz","year":"1991","unstructured":"Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY (1991) Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 148: 1064\u20131067","journal-title":"Am J Psychiatry"},{"key":"BF02246213_CR49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01250091","volume":"45","author":"HY Meltzer","year":"1979","unstructured":"Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC (1979) Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 45: 165\u2013175","journal-title":"J Neural Transm"},{"key":"BF02246213_CR50","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00007691-198802000-00011","volume":"10","author":"KK Midha","year":"1988","unstructured":"Midha KK, Cooper JK, Hawes EM, Hubbard JW, Korchinski ED, McKay G (1988) An ultrasensitive method for the measurement of haloperidol and reduced haloperidol in plasma by high-performance liquid chromatography with coulometric detection. Ther Drug Monit 10: 177\u2013183","journal-title":"Ther Drug Monit"},{"issue":"suppl","key":"BF02246213_CR51","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1097\/00002826-199001001-00008","volume":"13","author":"S Montgomery","year":"1990","unstructured":"Montgomery S, Baldwin D, Shah A (1990) Plasma level response relationships with fluoxetine and zimelidine. Clin Neuropharmacol 13 [suppl]: S71-S75","journal-title":"Clin Neuropharmacol"},{"key":"BF02246213_CR52","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/333174a0","volume":"333","author":"S Nedergaard","year":"1988","unstructured":"Nedergaard S, Bolam JP, Greenfield SA (1988) Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra. Nature 333: 174\u2013177","journal-title":"Nature"},{"key":"BF02246213_CR53","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0165-1781(90)90093-K","volume":"31","author":"JW Newcomer","year":"1989","unstructured":"Newcomer JW, Faustman WO, Yeh W, Csernansky JG (1989) Distinguishing depression and negative symptoms in unmediated patients with schizophrenia. Psychiatry Res 31: 243\u2013250","journal-title":"Psychiatry Res"},{"key":"BF02246213_CR54","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR (1962) The brief psychiatric rating scale (BPRS). Psychol Rep 10: 799\u2013812","journal-title":"Psychol Rep"},{"key":"BF02246213_CR55","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1007\/BF02245008","volume":"112","author":"MG Palfreyman","year":"1993","unstructured":"Palfreyman MG, Schmidt CJ, Sorensen SM, Dudley MW, Kehne JH, Moser P, Gittos MW, Carr AA (1993) Electrophysiological, biochemical and behavioral evidence for 5HT2 and 5HT3 mediated control of dopaminergic function. Psychopharmacology 112: S60-S67","journal-title":"Psychopharmacology"},{"key":"BF02246213_CR56","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0006-8993(85)90856-X","volume":"346","author":"A Pazos","year":"1985","unstructured":"Pazos A, Palacios J (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res 346: 205\u2013230","journal-title":"Brain Res"},{"key":"BF02246213_CR57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0006-8993(85)90857-1","volume":"346","author":"A Pazos","year":"1985","unstructured":"Pazos A, Cortes R, Palacios J (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin 2 receptors. Brain Res 346: 231\u2013249","journal-title":"Brain Res"},{"key":"BF02246213_CR58","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/schbul\/17.4.649","volume":"17","author":"P Plasky","year":"1991","unstructured":"Plasky P (1991) Antidepressant usage in schizophrenia. Schizophr Bull 17: 649\u2013657","journal-title":"Schizophr Bull"},{"key":"BF02246213_CR59","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/archpsyc.1979.01780050079010","volume":"36","author":"VA Prusoff","year":"1979","unstructured":"Prusoff VA, Williams DH, Weissman MM, Astrachan BM (1979) Treatment of secondary depression in schizophrenia. Arch Gen Psychiatry 36: 569\u2013575","journal-title":"Arch Gen Psychiatry"},{"key":"BF02246213_CR60","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/BF02439585","volume":"93","author":"MJ Raleigh","year":"1987","unstructured":"Raleigh MJ (1987) Differential behavioral effects of tryptophan and 5-hydroxytryptophan in vervet monkeys: influence of cate-cholaminergic systems. Psychopharmacology 93: 44\u201350","journal-title":"Psychopharmacology"},{"key":"BF02246213_CR61","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ddr.430080124","volume":"8","author":"A Reyntjens","year":"1986","unstructured":"Reyntjens A, Gelders Y, Hoppenbrouwers M-L, Van den Bussche G (1986) Thymostenic effects of ritanserin (R55667), a centrally active serotonin-S2 blocker. Drug Dev Res 8: 205\u2013211","journal-title":"Drug Dev Res"},{"key":"BF02246213_CR62","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/0006-3223(92)90279-9","volume":"31","author":"H Silver","year":"1992","unstructured":"Silver H, Nassar A (1992) Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 31: 698\u2013704","journal-title":"Biol Psychiatry"},{"key":"BF02246213_CR63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JWS (1970) Drug-induced extrapyramidal disorders. Acta Psychiatr Scand Suppl 212: 11\u201319","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"BF02246213_CR64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/schbul\/17.1.75","volume":"17","author":"SG Siris","year":"1991","unstructured":"Siris SG (1991) Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull 17: 75\u201397","journal-title":"Schizophr Bull"},{"key":"BF02246213_CR65","first-page":"331","volume":"27","author":"SG Siris","year":"1991","unstructured":"Siris SG, Bermanzohn PC, Gonzalez A, Mason SE, White CV, Shuwall MA (1991) The use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacol Bull 27: 331\u2013335","journal-title":"Psychopharmacol Bull"},{"key":"BF02246213_CR66","first-page":"1636","volume":"146","author":"P Sobin","year":"1989","unstructured":"Sobin P, Schneider L, McDermott H (1989) Fluoxetine in the treatment of agitated dementia (letter). Am J Psychiatry 146: 1636","journal-title":"Am J Psychiatry"},{"key":"BF02246213_CR67","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1176\/ajp.148.9.1279-a","volume":"148","author":"MH Stein","year":"1991","unstructured":"Stein MH (1991) Tardive dyskinesia in a patient taking haloperidol and fluoxetine (letter). Am J Psychiatry 148: 683","journal-title":"Am J Psychiatry"},{"key":"BF02246213_CR68","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00004714-199106000-00025","volume":"11","author":"AL Stoll","year":"1991","unstructured":"Stoll AL, Pope HG, McElroy SL (1991) High-dose fluoxetine: safety and efficacy in 27 cases (letter). J Clin Psychopharmacol 11: 225\u2013226","journal-title":"J Clin Psychopharmacol"},{"key":"BF02246213_CR69","first-page":"1263","volume":"148","author":"JA Stoukides","year":"1991","unstructured":"Stoukides JA, Stoukides CA (1991) Extrapyramidal symptoms upon discontinuation of fluoxetine (letter). Am J Psychiatry 148: 1263","journal-title":"Am J Psychiatry"},{"key":"BF02246213_CR70","first-page":"399","volume":"146","author":"JL Tate","year":"1989","unstructured":"Tate JL (1989) Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine (letter). Am J Psychiatry 146: 399\u2013400","journal-title":"Am J Psychiatry"},{"key":"BF02246213_CR71","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0165-1781(87)90122-3","volume":"20","author":"S Thiemann","year":"1987","unstructured":"Thiemann S, Csernansky J, Berger P (1987) Rating scales in research: the case of negative symptoms. Psychiatry Res 20: 47\u201355","journal-title":"Psychiatry Res"},{"key":"BF02246213_CR72","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0378-4347(92)80367-Y","volume":"579","author":"GA Torok-Both","year":"1992","unstructured":"Torok-Both GA, Baker GB, Coutts RT, McKenna KF, Aspeslet LJ (1992) Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection. J Chromatogr 579: 99\u2013106","journal-title":"J Chromatogr"},{"key":"BF02246213_CR73","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00442004","volume":"98","author":"L Ugedo","year":"1989","unstructured":"Ugedo L, Grenhoff J, Svensson TH (1989) Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98: 45\u201350","journal-title":"Psychopharmacology"},{"key":"BF02246213_CR74","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1600-0447.1980.tb00882.x","volume":"61","author":"J Waehrens","year":"1980","unstructured":"Waehrens J, Gerlach J (1980) Antidepressant drugs in anergic schizophrenia. Acta Psychiatr Scand 61: 438\u2013444","journal-title":"Acta Psychiatr Scand"},{"key":"BF02246213_CR75","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0014-2999(79)90110-9","volume":"55","author":"P Waldmeier","year":"1979","unstructured":"Waldmeier P, Delini-Stula A (1979) Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 55: 363\u2013373","journal-title":"Eur J Pharmacol"},{"key":"BF02246213_CR76","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.2042-7158.1983.tb02880.x","volume":"35","author":"J Williams","year":"1983","unstructured":"Williams J, Davies J (1983) The involvement of 5-hydroxytryptamine in the release of dendritic dopamine from slices of rat substantia nigra. J Pharm Pharmacol 35: 734\u2013737","journal-title":"J Pharm Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02246213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02246213\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02246213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T10:30:16Z","timestamp":1558002616000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02246213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,2]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1995,2]]}},"alternative-id":["BF02246213"],"URL":"https:\/\/doi.org\/10.1007\/bf02246213","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,2]]}}}